|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.54 USD | +0.28% |
|
-0.32% | +76.95% |
| 08-04 | Alkermes Insider Sold Shares Worth $2,239,076, According to a Recent SEC Filing | MT |
| 07-29 | Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALKERMES PLC | Other Biotechnology & Medical Research | +0.22% | -0.32% | +76.95% | +86.55% | +73.05% | 8.29B |  |  | |
- Stock Market
- Stocks
- ALKS Stock
- Charts Alkermes plc
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
